Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
CD19-specific chimeric antigen receptor (CAR)-modified T cells have antitumor activity in B cell malignancies, but factors that affect toxicity and efficacy have been difficult to define because of differences in lymphodepletion and heterogeneity of CAR-T cells administered to individual patients. We conducted a clinical trial in which CD19 CAR-T cells were manufactured from defined T cell subsets and administered in a 1:1 CD4(+)/CD8(+) ratio of CAR-T cells to 32 adults with relapsed and/or refractory B cell non-Hodgkin's lymphoma after cyclophosphamide (Cy)-based lymphodepletion chemotherapy with or without fludarabine (Flu). Patients who received Cy/Flu lymphodepletion had increased CAR-T cell expansion and persistence, and higher response rates [50% complete remission (CR), 72% overall response rate (ORR)] than patients who received Cy-based lymphodepletion without Flu (8% CR, 50% ORR). The CR rate in patients treated with Cy/Flu at the maximally tolerated dose was 64% (82% ORR; n = 11). Cy/Flu minimized the effects of an immune response to the murine single-chain variable fragment component of the CAR, which limited CAR-T cell expansion and clinical efficacy in patients who received Cy-based lymphodepletion without Flu. Severe cytokine release syndrome (sCRS) and grade ≥3 neurotoxicity were observed in 13 and 28% of all patients, respectively. Serum biomarkers, one day after CAR-T cell infusion, correlated with subsequent sCRS and neurotoxicity. Immunotherapy with CD19 CAR-T cells in a defined CD4(+)/CD8(+) ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progression-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“prolonged in vivo persistence of CAR-T cells has been correlated with the depth and durability of clinical responses [32, 36].”
From Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium (2025) · cites this paper as [36]
In the citing paper
“It is also known that lymphodepletion and the establishment of an optimal homeostatic cytokine environment is critical for robust CAR T-cell expansion and function.4,44,45”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Appio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112 · cited 3×
“We observed that treatment with the same lymphodepletion and CD19 CAR-T cell immunotherapy regimen resulted in lower CR rates in NHL and chronic lymphocytic leukemia (CLL) patients compared to B-ALL patients (1, 25).”
BackgroundResultSelf-citation
Research works printed but not linked: 2
- Gordis L Epidemiology 4 Philadelphia Saunders 2008
- Yeh ST Using trapezoidal rule for the area under a curve calculation Proceedings of the Twenty-Seventh Annual SAS User Group International (SUGI) Conference. Paper 229–27 2002
Cited by
Items 301–400 of 999
Maloney, D. G., Kuruvilla, J. G., Liu, F., Kostić, A., Kim, Y., Bonner, A., Zhang, Y., Fox, C. P., & Cartron, G. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01144-9 · Cited by 63
Engineering immune-evasive allogeneic cellular immunotherapies
Martin, K. E., Hammer, Q., Perica, K., Sadelain, M., & Malmberg, K. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01022-8 · Cited by 69
Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Jaeger-Ruckstuhl, C. A., Specht, J. M., Voutsinas, J. M., Macmillan, H., Wu, Q. V., Muhunthan, V., Berger, C., Pullarkat, S., Wright, J. H., Yeung, C. C. S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2172 · Cited by 64
“Administration of a (1:1) formulated EGFRt + CAR-T–cell product resulted in a greater expansion of CD8 + CAR-T cells over CD4 + CAR-T cells in most patients, similar to what was observed with CD19 CAR-T cells (47, 48).”
The why, what, and how of the new FACT standards for immune effector cells
Maus, M. V., & Nikiforow, S. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0239-0 · Cited by 58
“…e.g., frequent and durable response rates in B cell malignancies treated with CD19-directed chimeric antigen receptor (CAR) T cell trials [6 – 11], the field has grown tremendously, with an explosion of academic and commercial investigations using immune effector cells as a new platform of…”
BackgroundJin, Z., Xiang, R., Qing, K., Li, X., Zhang, Y., Wang, L., Zhu, H., Mao, Y., Xu, Z., & Li, J. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3368-8 · Cited by 63
Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?
Magnani, C. F., Tettamanti, S., Alberti, G., Pisani, I., Biondi, A., Serafini, M., & Gaipa, G. (2020) · Cells · doi:10.3390/cells9061337 · Cited by 68
de-Souza-Ferreira, M., Ferreira, É. E., & de‐Freitas‐Junior, J. C. M. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00770-4 · Cited by 70
“Engineering T-cells to express chimeric antigen receptors (CARs) targeting cancerassociated antigens has been found to be an effective tool to treat hematological neoplasms [145, 146], but to a lesser extent to treat solid tumors [147].”
BackgroundHirayama, A. V. V., Kimble, E. L., Wright, J. H., Fiorenza, S., Gauthier, J., Voutsinas, J. M., Wu, Q. V., Yeung, C. C. S., Gazeau, N., Pender, B. S., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011287 · Cited by 62
Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice
Pennell, C. A., Barnum, J. L., McDonald-Hyman, C. S., Panoskaltsis‐Mortari, A., Riddle, M. J., Xiong, Z., Loschi, M. L., Thangavelu, G., Campbell, H. M., Storlie, M. D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.006 · Cited by 59
Development of adaptive immune effector therapies in solid tumors
Comoli, P., Chabannon, C., Koehl, U., Lanza, F., Urbano-Ispizúa, Á., Hudecek, M., Ruggeri, A., Secondino, S., Bonini, C., & Pedrazzoli, P. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz285 · Cited by 65
iNKT: A new avenue for CAR-based cancer immunotherapy
Liu, Y., Wang, G., Chai, D., Dang, Y., Zheng, J., & Li, H. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101342 · Cited by 69
Knowns and Unknowns about CAR-T Cell Dysfunction
Titov, A., Kaminskiy, Y., Ganeeva, I., Zmievskaya, E., Valiullina, A., Rakhmatullina, A., Petukhov, A., Рифкатовна, М. Р., Rizvanov, A. A., & Bulatov, E. (2022) · Cancers · doi:10.3390/cancers14041078 · Cited by 59
Harnessing neoantigen specific CD4 T cells for cancer immunotherapy
Brightman, S. E., Naradikian, M. S., Miller, A. M., & Schoenberger, S. P. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri0220-603rr · Cited by 62
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy
Dunn, G. P., Cloughesy, T. F., Maus, M. V., Prins, R. M., Reardon, D. A., & Sonabend, A. M. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa154 · Cited by 61
Arbelaez, C. A., Estrada, J., Gessner, M. A., Glaus, C., Morales, A. B., Mohn, D., Phee, H., Lipford, J. R., & Johnston, J. A. (2020) · npj Vaccines · doi:10.1038/s41541-020-00253-9 · Cited by 56
Zhou, X., Tu, S., Wang, C., Huang, R., Deng, L., Song, C., Yue, C., He, Y., Yang, J., Zhao, L., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.564099 · Cited by 61
“The JCAR017 construct, which contains a truncated, cell surface version of human epidermal growth factor (EGFRt) and can be recognized and disabled by cetuximab, showed a superior safety profile in TRANSCEND NHL 001; the frequency of CRS (all, 35%; grade 3 or 4, 1%) and neurotoxicities (all, 19%; grade 3 or 4, 12%) we…”
ResultImpact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
Gauthier, J., Gazeau, N., Hirayama, A. V. V., Hill, J. A., Wu, V., Cearley, A., Perkins, P., Kirk, A., Shadman, M. S., Chow, V. A., et al. (2022) · Blood · doi:10.1182/blood.2021014497 · Cited by 61
Biscaia-Caleiras, M., Fonseca, N. A., Lourenço, A. S., Moreira, J. N., & Simões, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.021 · Cited by 62
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
Ghosh, A., Mailankody, S., Giralt, S. A., Landgren, C. O., Smith, E. L., & Brentjens, R. J. (2018) · Leukemia & Lymphoma · doi:10.1080/10428194.2017.1393668 · Cited by 55
CAR T cell therapy for B-cell lymphomas
Chávez, J. C., & Locke, F. L. (2018) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2018.04.001 · Cited by 68
“Bi-specific CARs targeting CD19 and CD22 are also in development and feasible in preclinical studies, and although majority of the trials focus on B-cell ALL CD22+, some include B-cell NHLs ( and ) [115].”
BackgroundInfluentialCTLA-4 tail fusion enhances CAR-T antitumor immunity
Zhou, X., Cao, H., Fang, S., Chow, R. D.-W., Tang, K., Majety, M., Bai, M., Dong, M. B., Renauer, P. A., Shang, X., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01571-5 · Cited by 62
Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma
Ghobadi, A. (2018) · Current Research in Translational Medicine · doi:10.1016/j.retram.2018.03.005 · Cited by 57
“(2016) [31] NCT01865617 I/II 4 Second gene with 4-1BB ac 1:1 CD4+/CD8”
BackgroundKunz, A., Gern, U., Schmitt, A., Neuber, B., Wang, L., Hückelhoven-Krauss, A., Michels, B., Hofmann, S., Müller-Tidow, C., Dreger, P., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.02.003 · Cited by 54
CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update
Cohen, A. D. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200889 · Cited by 57
CRISPR technology: The engine that drives cancer therapy
Zhang, M., Eshraghian, E. A., Jammal, O. A., Zhang, Z.-B., & Zhu, X. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111007 · Cited by 55
Toxicities following CAR-T therapy for hematological malignancies
Hernani, R., Benzaquen, A. O., & Solano, C. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102479 · Cited by 62
Innamarato, P., Kodumudi, K. N., Asby, S. C., Schachner, B. I., Hall, M. S., Mackay, A., Wiener, D. A., Beatty, M. S., Nagle, L., Creelan, B., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.025 · Cited by 53
George, P., Dasyam, N., Giunti, G., Mester, B., Bauer, E., Andrews, B., Perera, T., Ostapowicz, T., Frampton, C. M., Li, P., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034629 · Cited by 59
Ogasawara, K., Dodds, M., Mack, T. R., Lymp, J. F., Dell’Aringa, J., & Smith, J. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01039-5 · Cited by 51
Sudarsanam, H., Buhmann, R., & Henschler, R. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.886637 · Cited by 55
“…cell dose was found to be close to 106 cells/kg, whereas a cell dose higher than 107 cells/kg was associated with severe toxicity (Lee et al., 2015; Turtle et al., 2016a; Turtle et al., 2016b; Park et al., 2016; Gust et al., 2017; Wang and Han, 2018b; Fry et al., 2018; Dasyam et al., 2020; Siddiqi…”
BackgroundInfluentialOutcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
Bock, T., Colonne, C. K., Fiorenza, S., & Turtle, C. J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-00992-5 · Cited by 60
Progress and challenges in developing allogeneic cell therapies
Deuse, T., & Schrepfer, S. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.03.004 · Cited by 51
Ptáčková, P., Musil, J., Štach, M., Lesný, P., Němečková, Š., Král, V., Fábry, M., & Otáhal, P. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2017.10.001 · Cited by 54
Direct control of CAR T cells through small molecule-regulated antibodies
Park, S., Pascua, E., Lindquist, K. C., Kimberlin, C. R., Deng, X., Mak, Y. S. L., Melton, Z., Johnson, T., Lin, R., Boldajipour, B. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20671-6 · Cited by 58
Hong, R., Hu, Y., & Huang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627764 · Cited by 58
“ICANS complicated with CRS usually presents a short duration and lower severity (41, 81).”
BackgroundMetzger, M. L., & Mauz‐Körholz, C. (2019) · British Journal of Haematology · doi:10.1111/bjh.15789 · Cited by 60
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
Alhabbab, R. Y. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00312 · Cited by 53
Bechman, N., & Maher, J. F. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1857361 · Cited by 53
Meir, J., Abid, M. A., & Abid, M. B. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.09.016 · Cited by 52
“and better clinical outcomes compared with non-Flu-containing LD regimens [72].”
Yang, L., Yin, J., Wu, J., Qiao, L., Zhao, E. M., Cai, F., & Ye, H. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106612118 · Cited by 53
Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
Rentsch, V., Seipel, K., Banz, Y., Wiedemann, G., Porret, N. A., Bacher, U., & Pabst, T. (2022) · Cancers · doi:10.3390/cancers14102516 · Cited by 51
“Clinical response rates were reported to correlate with expansion levels and the duration of persistence of CAR T-cells [17,18].”
BackgroundOvercoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
García‐Guerrero, E., Sierro-Martínez, B., & Pérez‐Simón, J. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01128 · Cited by 51
“In this sense, increased CAR T-cell expansion has been observed in patients after the infusion of a defined 1:1 (CD4:CD8) CAR T-cell ratio (35, 105, 143).”
BackgroundJiang, P., Zhang, Z., Hu, Y., Liang, Z., Han, Y., Li, X., Zeng, X., Zhang, H., Zhu, M., Dong, J. W., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01676-0 · Cited by 53
Torres‐Collado, A. X., & Jazirehi, A. R. (2018) · Cancers · doi:10.3390/cancers10060200 · Cited by 48
“In a phase I/II trial, forty-one NHL patients were administered CD19CAR T cells containing a defined ratio of CD8+ and CD4+ CAR T cells; an objective response rate (ORR) of 84% and a complete response rate (CR) of 47% were observed in those who received CD19CAR T cells in addition to cyclophosphamide and fludarabine c…”
MethodMarofi, F., Rahman, H. S., Achmad, M. H., Sergeevna, K. N., Suksatan, W., Abdelbasset, W. K., Mikhailova, M. V., Shomali, N., Yazdanifar, M., Hassanzadeh, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.681984 · Cited by 54
RetractedInfusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers
Gu, X., Zhang, Y., Zhou, W., Wang, F., Yan, F., Gao, H., & Wang, W. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00542-2 · Cited by 53
Bulliard, Y., Freeborn, R. A., Uyeda, M. J., Humes, D. G., Bjordahl, R., VRIES, D. D., & Roncarolo, M. G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1509956 · Cited by 54
Ramachandran, M., Dimberg, A., & Essand, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.010 · Cited by 54
Zhou, X., Rasche, L., Kortüm, K. M., Danhof, S., Hudecek, M., & Einsele, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620312 · Cited by 54
RETRACTED ARTICLE: Hurdles to breakthrough in CAR T cell therapy of solid tumors
Marofi, F., Achmad, H., Bokov, D., Abdelbasset, W. K., Alsadoon, Z., Chupradit, S., Suksatan, W., Shariatzadeh, S., Hasanpoor, Z., Yazdanifar, M., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02819-x · Cited by 47
RetractedSensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR
Schanda, N., Sauer, T., Kunz, A. B., Hückelhoven‐Krauss, A., Neuber, B., Wang, L., Hinkelbein, M., Sedloev, D. N., He, B., Schubert, M., et al. (2021) · Cells · doi:10.3390/cells10113208 · Cited by 50
Challenges and innovations in CAR-T cell therapy: a comprehensive analysis
Luo, J., & Zhang, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1399544 · Cited by 56
Ansell, S. M., & Lin, Y. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129206 · Cited by 50
Chimeric antigen receptor–T cells with cytokine neutralizing capacity
Tan, A. H. J., Vinanica, N., & Campana, D. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001287 · Cited by 47
CAR T and CAR NK cells in multiple myeloma: Expanding the targets
Shah, U. A., & Mailankody, S. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101141 · Cited by 48
“Some patients developed anti-murine antibodies targeted towards the CARs that limited persistence and efficacy of reinfusions in non-Hodgkin’s lymphoma(55, 56) and renal cell carcinoma(57).”
BackgroundChimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
Tomuleasa, C., Fuji, S., Berce, C., Onaciu, A., Chira, S., Petrushev, B., Micu, W.-T., Moisoiu, V., Osan, C., Constantinescu, C. S., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00239 · Cited by 51
“Antibody-mediated depletion Phase I clinical trial Fred Hutchinson Cancer Center, Seattle, USA (88)”
BackgroundInfluentialCao, J., Wang, H., Gao, W., You, J., Wu, L.-H., & Wang, Z.-X. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.01.015 · Cited by 46
Mantle cell lymphoma and its management: where are we now?
Ladha, A., Zhao, J., Epner, E. M., & Pu, J. J. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0126-0 · Cited by 47
Mechanisms of resistance to CAR T cell therapies
Singh, N., Orlando, E. J., Xu, J., Xu, J., Binder, Z. A., Collins, M. A., O’Rourke, D. M., & Melenhorst, J. J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.002 · Cited by 50
CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
Elmas, E., Saljoughian, N., Pereira, M. D. S. F., Tullius, B. P., Sorathia, K., Nakkula, R. J., Lee, D. A., & Kararoudi, M. N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.834002 · Cited by 51
Li, W., Zhu, X., Xu, Y., Chen, J., Zhang, H., Yang, Z., Qi, Y., Hong, J., Li, Y., Wang, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1052717 · Cited by 54
Bright future or blind alley? CAR-T cell therapy for solid tumors
Zhang, K., Chen, H., Li, F., Sheng, H., Chen, F., & Li, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1045024 · Cited by 56
“in patients experiencing CRS, IL-6 was found to be highly elevated, which bas been believed to primarily mediate CRS onset (98).”
BackgroundSidana, S., Hosoya, H., Jensen, A. M., Liu, L., Goyal, A., Hovanky, V. N., Sahaf, B., Bharadwaj, S., Latchford, T. M., Arai, S., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00929-0 · Cited by 45
“…and cyclophosphamide (Flu/Cy) is superior to cyclophosphamide lymphodepletion alone in B cell malignancies, and is routinely used prior to investigational or standard-of-care BCMA CAR-T therapy [5], although the initial study of LCARB38M (subsequently cilta-cel) used cyclophosphamide alone [8].”
BackgroundAli, A., & DiPersio, J. F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1432799 · Cited by 52
Murty, S., Labanieh, L., Murty, T., Gowrishankar, G., Haywood, T., Alam, I. S., Beinat, C., Robinson, E. R., Aalipour, A., Klysz, D. D., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3579 · Cited by 43
Guo, Z., Tu, S., Yu, S., Wu, L., Pan, W., Chang, N., Zhou, X., Song, C., Li, Y., & He, Y. (2021) · Cancer Science · doi:10.1111/cas.14799 · Cited by 46
Reagan, P. M., & Neelapu, S. S. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01616 · Cited by 49
Mueller‐Schoell, A., Puebla‐Osorio, N., Michelet, R., Green, M. R., Künkele, A., Huisinga, W., Strati, P., Chasen, B., Neelapu, S. S., Yee, C., et al. (2021) · Cancers · doi:10.3390/cancers13112782 · Cited by 46
“These factors include the design of the CAR construct [8], the manufacturing protocol [9], the frequency of functionally active T cells in the manufacturing and infusion products [10], the T cell phenotype [11,12], and the CD4+/CD8+ subset composition [12,13] in the infusion product, the tumor burden [10], the tumor m…”
The promise of CAR T-cell therapy in aggressive B-cell lymphoma
Nair, R. K., & Neelapu, S. S. (2018) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2018.07.011 · Cited by 49
Heyman, B. M., & Yang, Y. (2019) · Cancers · doi:10.3390/cancers11020191 · Cited by 44
“Unfortunately, this has not provided the impressive clinical benefit in solid tumors as has been achieved for hematological malignancies [119].”
BackgroundRapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly
Munter, S. D., Parys, A. V., Bral, L., Ingels, J., Goetgeluk, G., Bonte, S., Pille, M., Billiet, L., Weening, K., Verhee, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030883 · Cited by 50
The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma
Manjunath, S. H., Cohen, A. D., Lacey, S. F., Suhoski, M. M., Garfall, A. L., Melenhorst, J. J., Maxwell, R., Arscott, W. T., Maity, A. M., Jones, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0308 · Cited by 52
“Taken together with the observation that incremental increases in the conditioning intensity improve engraftment and clinical outcomes (25, 38), it is possible that modifying the lymphodepletion (e.”
BackgroundLei, W., Zhao, A., Liu, H., Yang, C., Cheng, W., Guo, S., Chen, Z., Guo, Q., Li, L., Zhao, M., et al. (2024) · Cell Discovery · doi:10.1038/s41421-023-00625-0 · Cited by 56
Shen, X., Zhou, H., Zhou, X. M., Liu, Z., Meng, X., Zhang, L., Song, Y., Guo, R., Wang, F., Li, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53197-2 · Cited by 55
“image-based evaluation criteria rely solely on changes in tumor lesion size and cannot discern abnormal progression patterns, especially pseudoprogression, during immunotherapy 5,6 .”
Optimizing CAR T cell therapy for solid tumours: a clinical perspective
Li, J., Liu, C., Zhang, P., Shen, L., & Qi, C. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01075-1 · Cited by 56
Monitoring Immune Responses in Neuroblastoma Patients during Therapy
Szanto, C. L., Cornel, A. M., Vijver, S. V., & Nierkens, S. (2020) · Cancers · doi:10.3390/cancers12020519 · Cited by 45
Li, M., Xue, S., Tang, X., Xu, J., Chen, S., Han, Y., Qiu, H., Miao, M., Xu, N., Tan, J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-021-04296-3 · Cited by 50
Immunotherapies in rare cancers
Vivekanandhan, S., Bahr, D. A., Kothari, A., Ashary, M. A., Baksh, M., & Gabriel, E. M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01720-2 · Cited by 44
Wang, L., Fang, C., Kang, Q., Huang, W., Chen, Z., Zhao, W., Wang, L., Wang, Y., Tan, K., Xiao, G., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01105-8 · Cited by 44
Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells
Gowrishankar, K., Birtwistle, L., & Micklethwaite, K. P. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9756-5 · Cited by 49
Chimeric Antigen Receptor T-Cells: The Future Is Now
McHayleh, W. M., Bedi, P. S., Sehgal, R., & Solh, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020207 · Cited by 42
“It results from CD19 CAR T-cells targeting normal non-malignant CD19+ B-cells resulting in their elimination.”
InfluentialGargett, T., Truong, N. T., Ebert, L. M., Yu, W., & Brown, M. P. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.03.003 · Cited by 42
Schubert, M., Schmitt, A., Sellner, L., Neuber, B., Kunz, J. B., Wuchter, P., Kunz, A. B., Gern, U., Michels, B., Hofmann, S., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026644 · Cited by 44
“Turtle et al16 demonstrated that chemotherapy with flu and cyc preceding CAR T cell administration improved the outcome of treated patients.”
A Palette of Cytokines to Measure Anti-Tumor Efficacy of T Cell-Based Therapeutics
Ramesh, P., Shivde, R. S., Jaishankar, D., Saleiro, D., & Poole, I. C. L. (2021) · Cancers · doi:10.3390/cancers13040821 · Cited by 45
“Study 7: NCT01865617 [93] 37 patients: relapsed or refractory CD19+ NHL Serum concentrations IFN-γ IL-6, IL-8, IL-10, IL-15, TGF-β Luminex Assay 89% receiving CAR T cell infusion saw objective response.”
BackgroundPerica, K., Flynn, J. R., Curran, K. J., Rivere, I., Wang, X., Sénéchal, B., Halton, E. F., Diamonte, C., Pineda, J. P., Bernal, Y. J., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01196-3 · Cited by 42
Xia, Y., Zhang, J., Li, J., Zhang, L., Li, J., Fan, L., & Chen, L. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2136748 · Cited by 45
Ogasawara, K., Lymp, J. F., Mack, T. R., Dell’Aringa, J., Huang, C., Smith, J., Peiser, L., & Kostić, A. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2561 · Cited by 39
Amidi, Y., Eckhardt, C. A., Quadri, S. A., Malik, P., Firme, M. S., Jones, D. K., Jain, A., Danish, H. H., Rubin, D. B., Jacobson, C. A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005459 · Cited by 42
Schubert, M., Rohrbach, R., Schmitt, M. W., & Stein‐Thoeringer, C. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670286 · Cited by 40
Hont, A. B., Powell, A. B., Sohai, D. K., Valdez, I. K., Stanojevic, M., Geiger, A. E., Chaudhary, K., Dowlati, E. P., Bollard, C. M., & Cruz, C. C. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.002 · Cited by 42
Cummins, K. D., & Gill, S. I. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1375107 · Cited by 43
“The use of pembrolizumab (a PD-1 receptor blocking humanized antibody) is currently being evaluated in a phase 1/2 trial at the University of Pennsylvania, recruiting patients with a CD19þ B-NHL who have failed CART-19 therapy after this approach proved successful in a single patient with primary refractory DLBCL for…”
MethodInfluentialToward precision manufacturing of immunogene T-cell therapies
Xu, J., Melenhorst, J. J., & Fraietta, J. A. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2017.12.007 · Cited by 38
Biomarkers in individualized management of chimeric antigen receptor T cell therapy
Du, M., Hari, P., Hu, Y., & Mei, H. (2020) · Biomarker Research · doi:10.1186/s40364-020-00190-8 · Cited by 39
Al-Mansour, M. M., Al‐Foheidi, M., & Ibrahim, E. M. (2020) · Molecular and Clinical Oncology · doi:10.3892/mco.2020.2103 · Cited by 48
A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy
Cai, C., Tang, D., Han, Y., Shen, E., Abdihamid, O., Guo, C., Shen, H., & Zeng, S. (2020) · Aging · doi:10.18632/aging.104058 · Cited by 41
Makita, S., Imaizumi, K., Kurosawa, S., & Tobinai, K. (2019) · Drugs in Context · doi:10.7573/dic.212567 · Cited by 42
Louie, R. H. Y., Cai, C., Samir, J., Singh, M., Deveson, I. W., Ferguson, J. M., Amos, T. G., McGuire, H. M., Gowrishankar, K., Adikari, T. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43656-7 · Cited by 41
“Treatment with cyclophosphamide/ fl udarabine prior to cell infusion has been associated with CAR T cell persistence in patients with acute lymphoblastic leukaemia 20,21 .”
Canelo‐Vilaseca, M., Sabbah, M., Blasi, R. D., Cristinelli, C., Sureda, A. M., Caillat‐Zucman, S., & Thiéblemont, C. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02539-9 · Cited by 43
CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before
Ghilardi, G., Brændstrup, P., Chong, E. A., Schuster, S. J., Svoboda, J., & Ruella, M. (2020) · British Journal of Haematology · doi:10.1111/bjh.17191 · Cited by 38
“CART products enriched in central memory T cells (Tcm) were associated with higher expansion, persistence and increased cytotoxic activity compared to CART products enriched with more differentiated T cells.75 Additional pre- clinical evidence supports that CART generated from less-dif- ferentiated T cells have superi…”
MethodInfluentialLoo, L., Harris, S., Milton, M., Meena, M., Lembke, W., Berisha, F., Bertholet, S., Dessy, F. J., Dodge, R. W., Fang, X., et al. (2022) · Bioanalysis · doi:10.4155/bio-2022-0081 · Cited by 41
Metadata
- Authors
- Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., Soma, L., Wood, B., Li, D., Heimfeld, S., Riddell, S. R., & Maloney, D. G.
- Affiliations
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Juno Therapeutics (United States) (US)
- Corresponding author
- Turtle, Cameron J.
- Riddell, Stanley R.
- Maloney, David G.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-09-07
- Volume
- 8
- Issue
- 355
- Pages
- 355ra116-355ra116
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5045301
- OpenAlex
- W2509364267
- Semantic Scholar
- af93b35d4d1ed32f3de2e434b4049004928a60bc
- Cited by
- 1,016
- References
- 38
- Citations by year
- 2026: 37 · 2025: 60 · 2024: 101 · 2023: 78 · 2022: 113 · 2021: 120 · 2020: 153 · 2019: 139 · 2018: 121 · 2017: 85 · 2016: 6
- FWCI
- 63.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01 CA136551)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK56465)
- NCI (P30 CA15704)
- Life Science Discovery Fund
- Bezos Family Foundation
- Juno Therapeutics
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CAR T-cell therapy, non-Hodgkin lymphoma, B-cell lymphoma, CD4/CD8 ratio, lymphocyte depletion, cyclophosphamide, fludarabine, cytokine release syndrome, neurotoxicity, serum biomarkers, CAR T cell persistence, relapsed/refractory lymphoma
- MeSH terms
- Adult, Aged, Cyclophosphamide, Female, Humans, Immunotherapy, Lymphocyte Depletion, Lymphoma, Non-Hodgkin, Male, Middle Aged, Receptors, Antigen, T-Cell, Syndrome, Biomarkers, Tumor, Vidarabine, CD4-Positive T-Lymphocytes, Lymphocyte Subsets, Treatment Outcome, CD8-Positive T-Lymphocytes, Transgenes, Cell Proliferation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.